TD Private Client Wealth LLC Sells 11,575 Shares of DexCom, Inc. $DXCM

TD Private Client Wealth LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 94.2% during the 4th quarter, HoldingsChannel reports. The fund owned 712 shares of the medical device company’s stock after selling 11,575 shares during the quarter. TD Private Client Wealth LLC’s holdings in DexCom were worth $47,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in DXCM. Brighton Jones LLC lifted its position in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC lifted its position in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares in the last quarter. Empowered Funds LLC lifted its position in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares in the last quarter. Focus Partners Wealth lifted its position in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after buying an additional 258 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,112 shares of company stock worth $379,990 over the last 90 days. 0.28% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wells Fargo & Company cut their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Raymond James Financial set a $81.00 price target on shares of DexCom in a research report on Friday, May 1st. Mizuho set a $75.00 price target on shares of DexCom in a research report on Friday, May 1st. William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Finally, Truist Financial reissued a “buy” rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.21.

DexCom Stock Up 0.3%

DexCom stock opened at $72.10 on Friday. The firm has a market capitalization of $27.82 billion, a PE ratio of 30.81, a P/E/G ratio of 1.19 and a beta of 1.40. The company’s 50-day moving average is $63.58 and its 200-day moving average is $65.98. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.